I favor holding onto these players for the long term to truly benefit from their earnings potential.
The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) collaborated on. While the news will certainly help the pharmaceutical companies' bottom lines, it's important to look deeper to see if any of these three stocks make a solid investment today. At first glance, Pfizer's stock appears to be a screaming deal.
Two candidates with loads of potential are Moderna (NASDAQ: MRNA) and Teladoc Health (NYSE: TDOC). Moderna's earnings soared over the past two years thanks to its blockbuster COVID-19 vaccine. Moderna has set out a plan that could result in $30 billion in sales down the road, which surpasses its peak of about $18 billion in coronavirus vaccine sales.